PT-141 for menopause-related sexual dysfunction: what the evidence says

What's this video probably claiming?

Based on the caption and hashtag context, Blair Critch is almost certainly presenting PT-141 (bremelanotide) as a solution for the libido and sexual function changes that come with menopause. The pitch follows a familiar format: personal testimony, a sense of discovery, and an implied message that this peptide restored something menopause was taking away. She likely describes it as working in both men and women, possibly mentions it being approved by the FDA, and frames the experience as dramatically positive. Creators in the menopause-mentor space often position peptides like PT-141 as empowering alternatives to traditional hormone therapy, sometimes leaving out the parts that make a clinician wince. The hashtag choices here point to an audience of women over 40 looking for answers their doctors may not have mentioned, which makes the framing choices worth scrutinizing closely.

What does the science actually show?

PT-141 is not an invented wellness compound. Bremelanotide received FDA approval in 2019 under the brand name Vyleesi, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. The important trial published by Simon et al. (2019, Obstetrics and Gynecology) showed statistically significant improvements in desire scores versus placebo, but the effect sizes were modest. About 25% of participants on bremelanotide reported a meaningful increase in satisfying sexual events compared to 17% on placebo. Nausea was the most common side effect, affecting roughly 40% of users. Critically, the approved indication is premenopausal women, not menopausal women, which is a regulatory distinction that matters. A melanocortin receptor agonist, it works centrally on the brain rather than genitally, which is mechanistically interesting but also means cardiovascular effects including transient blood pressure increases are real and documented.

Where does the social media noise diverge from clinical reality?

The gap between TikTok PT-141 content and clinical reality opens in several places. First, the off-label use in menopausal women. The FDA approval is for premenopausal HSDD. Using it during menopause is not evidence-based in the same regulatory sense, and no large randomized controlled trials have established safety or efficacy specifically in this population. Second, the compounded peptide market. Most PT-141 circulating in telehealth and peptide communities is not FDA-approved Vyleesi. It is compounded bremelanotide, which is a different product legally and sometimes chemically. Claiming equivalence between the two is something no responsible provider should do. Third, the nausea issue is frequently minimized. In clinical data, it was severe enough that roughly 13% of participants in the Simon 2019 trial discontinued due to side effects. Fourth, the blood pressure signal is real. A transient increase of 6-12 mmHg systolic is documented, which matters in midlife women who already face cardiovascular risk shifts post-menopause.

What should you actually know?

If you are a woman in menopause experiencing low libido or sexual dysfunction, PT-141 is not your only or necessarily best option. The American College of Obstetricians and Gynecologists recommends addressing genitourinary syndrome of menopause (GSM) with vaginal estrogen as a first-line intervention for many women, and evidence supports this approach. For HSDD specifically, flibanserin (Addyi) has FDA approval for premenopausal women and a different mechanism. Neither drug is a magic solution. The honest framing is that menopause-related sexual dysfunction is multifactorial, involving hormonal shifts, relationship context, sleep quality, and mental health, none of which a peptide injection addresses alone. Anyone considering PT-141 should have a proper cardiovascular history taken, understand the nausea risk, and ideally work with a provider who is not also selling the compound. FormBlends does not recommend or prescribe specific doses of any peptide through editorial content.